[go: up one dir, main page]

CL2017003201A1 - Variantes de il-37 - Google Patents

Variantes de il-37

Info

Publication number
CL2017003201A1
CL2017003201A1 CL2017003201A CL2017003201A CL2017003201A1 CL 2017003201 A1 CL2017003201 A1 CL 2017003201A1 CL 2017003201 A CL2017003201 A CL 2017003201A CL 2017003201 A CL2017003201 A CL 2017003201A CL 2017003201 A1 CL2017003201 A1 CL 2017003201A1
Authority
CL
Chile
Prior art keywords
polypeptides
invention refers
compositions
sequence
inflamming
Prior art date
Application number
CL2017003201A
Other languages
English (en)
Inventor
Marcel Nold
Claudia Nold
Andrew Ellisdon
James Whisstock
Original Assignee
Univ Monash
Hudson Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902262A external-priority patent/AU2015902262A0/en
Application filed by Univ Monash, Hudson Inst Med Res filed Critical Univ Monash
Publication of CL2017003201A1 publication Critical patent/CL2017003201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>ESTA INVENCIÓN SE REFIERE A POLIPÉPTIDOS, QUE INCLUYEN VARIANTES DE INTERLEUCINA-37 (IL-37), Y AGENTES TERAPÉUTICOS Y COMPOSICIONES RELACIONADAS. LA INVENCIÓN SE REFIERE, ADEMÁS, AL USO DE LOS POLIPÉPTIDOS Y COMPOSICIONES EN MÉTODOS PARA TRATAR ENFERMEDADES O AFECCIONES INFLAMATORIAS. LA PRESENTE INVENCIÓN PROPORCIONA UN POLIPÉPTIDO ANTINFLAMATORIO MONOMÉRICO QUE COMPRENDE UNA SECUENCIA DE AMINOÁCIDOS DE UN MONÓMERO DE IL-37, LA SECUENCIA DE AMINOÁCIDOS TIENE UNA MUTACIÓN O MODIFICACIÓN PARA EVITAR QUE EL PÉPTIDO ANTINFLAMATORIO FORME UN HOMODÍMERO.</p>
CL2017003201A 2015-06-15 2017-12-14 Variantes de il-37 CL2017003201A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015902262A AU2015902262A0 (en) 2015-06-15 IL-37 variants
AU2016900703A AU2016900703A0 (en) 2016-02-26 IL-37 variants (2)

Publications (1)

Publication Number Publication Date
CL2017003201A1 true CL2017003201A1 (es) 2018-07-20

Family

ID=57544698

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003201A CL2017003201A1 (es) 2015-06-15 2017-12-14 Variantes de il-37

Country Status (17)

Country Link
US (2) US11084855B2 (es)
EP (1) EP3307767B1 (es)
JP (2) JP2018522547A (es)
KR (1) KR20180034390A (es)
CN (1) CN107849109A (es)
AU (3) AU2016281189B2 (es)
CA (1) CA2987437C (es)
CL (1) CL2017003201A1 (es)
CO (1) CO2017013404A2 (es)
CR (1) CR20180008A (es)
HK (1) HK1251001A1 (es)
IL (1) IL256253A (es)
MX (1) MX2017016195A (es)
PE (1) PE20180691A1 (es)
PH (1) PH12017550134A1 (es)
RU (1) RU2017144571A (es)
WO (1) WO2016201503A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167592A (zh) * 2016-12-23 2019-08-23 莫纳什大学 抗il-37抗体
US11524985B2 (en) 2017-03-20 2022-12-13 Bio-Techne Corporation IL-37 fusion protein and methods of making and using same
CN114846024A (zh) * 2019-12-20 2022-08-02 豪夫迈·罗氏有限公司 Il-37融合蛋白及其用途
US20240075144A1 (en) * 2021-01-08 2024-03-07 Emory University Interleukin-37, Chimeric Antigen Receptors, Nucleic Acids, and Vectors Encoding the Same and Uses in Cancer Therapies
CN116236560A (zh) * 2022-12-13 2023-06-09 华中科技大学同济医学院附属同济医院 人白细胞介素-37b在制备治疗鼻息肉的药品中的应用
WO2024145365A2 (en) * 2022-12-27 2024-07-04 Arete Discoveries, Inc. Compositions for the diagnosis, treatment, prevention, and alleviation of neurodegenerative and autoimmune disorders
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
CN118546232B (zh) * 2024-07-24 2025-02-11 东北农业大学 一种植物源重组IL-37a蛋白及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DK1225226T3 (da) 1992-03-13 2008-04-14 Biomerieux Bv Peptider og nucleinsyresekvenser beslægtet med Epstein-Barr-virus
JP2001512002A (ja) * 1997-08-04 2001-08-21 ミレニアム ファーマシューティカルズ インク． Ｔａｎｇｏ−７７関連蛋白質ファミリーの新規分子およびその使用
AU6386399A (en) * 1998-09-18 2000-04-10 Schering Corporation Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
US6680380B1 (en) * 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
US20030148467A1 (en) * 1998-10-27 2003-08-07 Zymogenetics, Inc. Interleukin-1 homolog zil1a4
CA2348431A1 (en) * 1998-10-27 2000-05-04 Zymogenetics, Inc. Interleukin-1 homolog zil1a4
US7033783B2 (en) 1998-12-14 2006-04-25 Immunex Corp. Polynucleotide encoding IL-1 zeta polypeptide
ES2325165T3 (es) * 1998-12-14 2009-08-27 Immunex Corporation Polipeptidos y dna de xrec2.
EP1233977A1 (en) * 1999-12-01 2002-08-28 SmithKline Beecham Corporation Interleukin-1 homologue, mat il-1h4
US20020187512A1 (en) * 2001-09-10 2002-12-12 Nagem Ronaldo Alves Pinto Crystal structure of human interleukin-22
US20130225437A1 (en) * 2010-08-16 2013-08-29 THE REGENTS OF THE UNIVERSITY OF COLORADO , a body corporation Biomarkers of cancer
US20140275229A1 (en) 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
CN104083755A (zh) * 2013-11-21 2014-10-08 深圳意达凯生物科技有限公司 含白细胞介素37的药物、其制备方法及应用
CA2901370A1 (en) * 2014-08-25 2016-01-18 Shengwu Ma Production of il-37 in plants

Also Published As

Publication number Publication date
JP7306655B2 (ja) 2023-07-11
CR20180008A (es) 2018-06-12
HK1251001A1 (zh) 2019-01-18
CO2017013404A2 (es) 2018-05-21
MX2017016195A (es) 2018-09-11
US20180162918A1 (en) 2018-06-14
KR20180034390A (ko) 2018-04-04
AU2021201335A1 (en) 2021-03-18
US11084855B2 (en) 2021-08-10
JP2020191860A (ja) 2020-12-03
EP3307767B1 (en) 2022-01-12
AU2016281189B2 (en) 2019-03-07
EP3307767A1 (en) 2018-04-18
CA2987437C (en) 2024-04-09
WO2016201503A1 (en) 2016-12-22
EP3307767A4 (en) 2018-12-05
RU2017144571A (ru) 2019-07-15
IL256253A (en) 2018-02-28
JP2018522547A (ja) 2018-08-16
PE20180691A1 (es) 2018-04-23
RU2017144571A3 (es) 2019-10-17
US20220073580A1 (en) 2022-03-10
PH12017550134A1 (en) 2018-03-05
CA2987437A1 (en) 2016-12-22
AU2016281189A1 (en) 2017-12-21
CN107849109A (zh) 2018-03-27
AU2019203989A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
CL2017003201A1 (es) Variantes de il-37
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
CL2017000999A1 (es) Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
MX2021009673A (es) Moduladores de ror-gamma.
CL2017002345A1 (es) Un nuevo complejo que comprende un péptido de penetración celular, una molécula cargo y un agonista peptídico de tlr
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
UY37456A (es) Inmunoglobulinas y sus usos
MX392683B (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
CO2018003224A2 (es) Formulaciones de aminoacidos de liberacion modificada administradas oralmente
DK3658132T3 (da) Sammensætninger omfattende aminosyrer til anvendelse ved behandling af mitokondrielle dysfunktion-relaterede sygdomme
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
MX2019012452A (es) Meganucleasas diseñadas especificas para secuencias de reconocimiento en el gen pcsk9.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
CO2016000671A1 (es) Construcciones de variantes de sirp-alfa y sus usos